An Oral Small Molecule VEGFR2 Inhibitor, Apatinib, in Patients with Recurrent or Refractory Cervical Cancer: A Real World Study

Table 2

Analysis of patient safety.

Adverse event	N (%)
G1 hypertension	19 (65.5)
G1 mucositis	16 (55.2)
G1-2 hand-foot syndrome	13 (44.8)
G1-2 proteinuria	6 (20.7)
G3 proteinuria	1 (3.4)
G4	0 (0)

G: grade.